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excluded. Cox proportional hazard models were built to predict
the time dependent likelihood of no recurrence, as a function of
drug persistence, for patients who start on clopidogrel, warfarin
or aspirin, adjusting for blood pressure lowering and lipid low-
ering drugs taken after the ﬁrst stroke, hypertension, heart
disease, diabetes, race, gender, age and residence (urban or not).
RESULTS: In total, there were 925 patients, 36% older than 60,
58% African Americans, and 35% males. Patients who persist
on the ﬁrst drug taken post-stroke (HR = 1.29, p = 0.03, CI
1.02–1.63), start on clopidogrel (HR = 1.42, p = 0.006 CI
1.10–1.82) or take up to two (HR = 1.43, p = 0.001, CI
1.15–1.78) blood pressure lowering drugs post-stroke are sig-
niﬁcantly more likely to have no recurrence. Patients with a diag-
nosis of heart disease (HR = 0.81, p = 0.05, CI 0.66–0.99),
hypertension (HR = 0.64, p = 0.00, CI 0.51–0.79) or diabetes
(HR = 0.75, p = 0.006, CI 0.61–0.92) post-stroke are less likely
to have no recurrence, i.e. to stay in remission after the ﬁrst
stroke. CONCLUSIONS: Among Medicaid patients, persistence
on the ﬁrst drug taken after a stroke reduces the likelihood of
recurrence. Clopidogrel and the combination of up to two blood
pressure lowering drugs are associated with a higher likelihood
of no recurrence. However, heart disease, hypertension and dia-
betes decrease the likelihood of avoiding a second stroke. These
results may inform care management plans for Medicaid
patients.
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OBJECTIVES: Disability presents a major economic and human-
istic burden among stroke survivors. To quantify disability in
patients, activities of daily living (ADLs) measures have been
used. The translation among measures, however, has not been
developed, leaving a signiﬁcant discontinuation of patient care
between facilities that use different measures. The purpose of 
this study is to develop a conversion system for two most widely
used ADL measures, the Motor component in Functional 
Independence Measure (M-FIM) and the Barthel Index (BI).
METHODS: We use Kansas City Stroke Study data. We stan-
dardized the scales of both instruments to 0–1 and rotated them
45 degrees in order to get a consistent conversion scheme regard-
less of the direction of the conversion (from BI to M-FIM or from
M-FIM to BI). We applied the censored heteroscedastic regres-
sion spline model using Monte Carlos Expectation and Condi-
tional Maximization (MCECM) algorithm, since the data is
censored in both boundaries (for M-FIM: 13–91, and BI: 0–100)
with ceiling and ﬂoor effects. RESULTS: Among 1676 records,
2.4% and 5.8% of M-FIM records, and 3.5% and 24% of BI
presented the lowest and highest scores respectively. Based on
our model, zero, 60, and 100 of BI scores are equivalent to 13
to 15, 59 to 62, and 88 to 91 of M-FIM. (Complete conversion
table will be provided in the presentation.) The two measures
were highly correlated (r = 0.9479, p < 0.0001), but the linear-
ity assumption was improper, particularly, for the higher score
range of the M-FIM and BI. CONCLUSIONS: For the contin-
uum of patient care, the conversion among scales is an impor-
tant issue. We developed a conversion scheme between two
widely used ADL measures, BI and M-FIM, based on their total
scores. Further research is planned to obtain a more robust and
precise conversion model addressing item level information.
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OBJECTIVES: We aimed to determine whether, and by how
much, stroke severity, as measured by the Modiﬁed Rankin Scale
(MRS) of disability, inﬂuences the duration of subsequent dis-
ability, and therefore the need for rehabilitation and nursing care.
METHODS: A total of 7599 patients were enrolled in a ran-
domised clinical trial (MATCH) of clopidogrel vs. aspirin +
clopidogrel after a transient ischaemic attack or ischaemic stroke
within 90 days (median 15 days). The two study arms were
pooled. The Modiﬁed Rankin Scale (MRS) was assessed at: base-
line (randomisation), months one, three, six, 12, 18 and follow-
ing a recurrent stroke. RESULTS: At baseline, 20.7% of 7599
patients were disabled (11.6% at MRS 3, 8.6% at MRS 4 and
0.5% at MRS 5). Median time to change from disabled state
(MRS 3, 4, or 5) to non-disabled state (MRS 0, 1, or 2) was
three-months for patients with moderate disability (MRS 3) and
18 months for patients with severe disability (MRS 4). For
patients with very severe disability (MRS 5), 80.7% remained
disabled at 18-months. Among the 804 patients who experienced
a recurrent ischaemic stroke during the study, 53.4% of patients
were disabled after the recurrent stroke (20.3% at MRS 3,
20.8% at MRS 4, and 12.3% for MRS 5). Median time to
change from disabled state to non-disabled state was six-months
for MRS 3 and more than 18-months for MRS 4. For MRS 5,
94.5% of patients still remained disabled. CONCLUSIONS:
More severe strokes and recurrent strokes cause longer-term dis-
ability. After a recurrent stroke, the median time to change from
a disabled to non-disabled state is six-months for patients with
moderate disability (MRS 3) and more than 18-months for
patients with severe disability (MRS 4). Almost all patients with
very severe disability (MRS 5), remain disabled and require per-
manent nursing care.
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ECONOMIC EVALUATION OF SIROLIMUS-ELUTING STENTS
IN JAPAN
Kobayashi M, Ikeda S
Keio University School of Medicine,Tokyo, Japan
OBJECTIVES: Percutaneous coronary intervention (PCI) using
a sirolimus-eluting stent (SES), coated with the immunosuppres-
sive agent sirolimus, dramatically reduces the risk of restenosis
compared to bare metal stent (BMS) implantation. However,
before SES can be widely adopted in clinical practice, it is essen-
tial to conduct an economic evaluation of this effective but
expensive device. Our study was undertaken to estimate the
three-year cumulative medical costs of stenting using SES com-
pared to BMS in the Japanese health care system. METHODS:
The data on clinical sequelae of stenting using BMS were derived
from our previous study, based on data collected from three
Japanese hospitals. We estimated that the probability of target-
lesion revascularization would be 0.15 times in SES implantation
compared to BMS implantation based on the recent meta-
analysis results (Babarille et al, 2004). The medical costs for pro-
cedures were obtained from published articles and were adjusted
to the January, 2005 level. Annual discount rate was set to 0.03.
Sensitivity analyses with different presumptions, including the
cost of intervention, the probability of target-lesion revascular-
337Abstracts
ization, and discount rate, were undertaken. RESULTS: In the
ﬁrst admission to perform PCI, the medical cost of the SES
patient was approximately 0.16m Japanese Yen higher than that
of the BMS patient. However, the expected three-year cumula-
tive medical cost per patient to be approximately 0.35m Yen
lower in the SES patient (2.07m Yen) than in the BMS patient
(2.43m Yen) because the revascularization rate was lower in the
SES patient. Extensive sensitivity analyses conﬁrmed that the
economic advantage of SES over BMS was quite robust. CON-
CLUSIONS: We concluded that the use of SES is likely to be a
cost-saving option as compared with BMS implantation within
the context of the Japanese health care system. Prospective eco-
nomic studies with long follow-up are needed to conﬁrm our
simulation results.
PST2
INPATIENT RESOURCE UTILIZATION AND COSTS OF
PROCEDURES IMPLANTING DRUG-ELUTING STENTS IN
COMPLEX CASES:THE ARRIVE REGISTRY
Olchanski N1, Clark MA1, Cohen D2
1Boston Scientiﬁc Corporation, Natick, MA, USA; 2Beth Israel
Deaconess Medical Center, Boston, MA, USA
OBJECTIVES: There are no published “real world” data for
costs of drug-eluting stenting procedures with the TAXUS 
Paclitaxel-Eluting Stent System. Whether Medicare payments
sufﬁciently cover costs of cases with comorbidities has not 
been investigated. METHODS: We analyzed resource utilization
data from ARRIVE, a prospective, multicenter, community-
hospital-based single arm US registry capturing 2590 consecu-
tive patients treated with the TAXUS stents at 50 sites. 
Procedural costs were calculated for subgroups with comorbidi-
ties of diabetes, renal disease, multivessel disease, congestive
heart failure, left main disease, acute myocardial infarction (MI),
and combinations of above conditions. Medical devices were
priced using 2004 national average prices, and procedural med-
ications using 2004 average wholesale prices. Hospitalization
costs were calculated using the 2003 MedPAR ﬁles, adjusted to
2004 costs. RESULTS: As shown in the table below, patients
with one or more comorbid conditions on average had higher
resource utilization and costs, ranging from $16,077 for left
main disease to $27,116 for renal disease (largely driven by the
length of stay). CONCLUSIONS: Stenting cases with severe
comorbidities incur higher costs than overall average. Average
Medicare payments in 2003 were $17,441 for patients with MI
(DRG 526) and $13,999 without MI (DRG 527). Clearly MI is
not the only comorbid condition that drives high inpatient costs.
The current DRG structure is not giving fair payments for
patients with certain high-cost comorbidities. 
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OBJECTIVES: Symptomatic intracranial atherosclerosis (IA) has
an annual stroke risk of 5%–20%. The study objectives were: 1)
to assess economics of existing and emerging IA stenting (IAS)
technologies; and 2) estimate the effect of IAS versus anti-platelet
therapy (APL) on stroke risk, overall survival (OS), quality-
adjusted life years (QALYs), costs, and cost-utility (CU).
METHODS: A Markov model was developed to compare IAS
with APL from a US perspective in patients with symptomatic
IA. The model included the following parameters: 1) procedural
complications; 2) restenosis rates; 3) stroke rates of patent or
stenosed vessels; 4) mortality after stroke; 5) utilities; and 6)
costs of procedure, strokes, and unrelated future resource use.
Procedural outcomes of the current model are based on litera-
ture ﬁndings. Costs in $US 2004 and beneﬁts were discounted
at ﬁxed annual rate of 3%. Sensitivity analysis was also per-
formed on the above parameters. RESULTS: With IAS, 74% of
patients had patent vessel at six-months; 18% of patients expe-
rienced restenosis by 12 months, 11.3% of patients had a pro-
cedural complication (3.3% stroke, 6.3% non-stroke, 1.7%
death). Stroke risk is predicted to decline from 7.3%/yr from the
stenosed, target vessel to 0.5%/yr with patent vessel; and 5%/yr
stroke risk in non-target vessels. Over ﬁve years, stroke risk is
predicted to decline from 44% with APL to 31% for IAS. OS
thus is expected to increase by 0.33 years, and 0.24 QALYs. The
average cost per IAS procedure is $9,731, with a predicted
$8,366 reduction in stroke-related costs and cost-utility of IAS
vs APL of $19,963 over a 10-year time horizon. CONCLU-
SIONS: The cost-effectiveness model shows that IA stenting is
predicted to substantially reduce stroke rate, increase overall sur-
vival and QALY relative to antiplatelet therapy. The projected
CU ratio is considered within acceptable adoption ranges in the
US.
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DRUG-ELUTING VERSUS BARE-METAL CORONARY STENTS:
6-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A
CONTROLLED STUDY FOR THE REDUCTION OF CORONARY
RESTENOSIS
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OBJECTIVE: To evaluate the long-term outcomes of drug-
eluting stents in comparison to bare-metal stents in conventional
Renal Multivessel 
Overall Diabetes Disease Disease 
(n = 1968) (n = 586) (n = 48) (n = 707)
Proc. 
Duration 54.6 55.4 68.2 60.8
(min)
Stents 
implanted 1.7 1.71 1.65 1.82
Gp IIb/IIIa 35.3% 35.1% 28.4% 33.3%
Inhibitor
Length of 2.7 3 7.4 3
stay (days)
Total Cost $15,858 $16,641 $27,116 $17,131
Congestive Left Main >=1 
Heart Failure Disease Acute MI comorbidities
(n = 239) (n = 109) (n = 181) (n = 1223) 
Proc. 
Duration 60.4 64.4 57.1 57.0 
(min)
Stents 
implanted 1.7 1.7 1.7 1.7 
Gp IIb/IIIa 33.9% 41.6% 46.6% 34.7% 
Inhibitor
Length of 3.7 2.6 3.6 2.9 
stay (days)
Total Cost $18,520 $16,077 $18,162 $16,408
